Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Hong-jie, Wang, Yu, Zhang, Meng-qi, Xie, Yuan-chao, Wu, Qing-qing, Liang, Li-yu, Cao, Ye, Duan, Hua-qing, Tian, Guang-hui, Ma, Juan, Zhang, Zhuo-bing, Li, Ning, Jia, Jing-ying, Zhang, Jing, Aisa, Haji Akber, Shen, Jing-shan, Yu, Chen, Jiang, Hua-liang, Zhang, Wen-hong, Wang, Zhen, Liu, Gang-yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924727/
https://www.ncbi.nlm.nih.gov/pubmed/35296780
http://dx.doi.org/10.1038/s41401-022-00895-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924727/
https://www.ncbi.nlm.nih.gov/pubmed/35296780
http://dx.doi.org/10.1038/s41401-022-00895-6

Ejemplares similares